Global regulatory bodies are increasingly converging around the adoption of New Approach Methodologies (NAMs) in drug development.

Regulators including the FDA, NIH, EMA, PMDA, and UK authorities are aligning their policy directions toward more human relevant and decision focused evaluation frameworks, with the shared goal of reducing reliance on animal based testing. As this alignment continues to strengthen across regions, microphysiological systems, or MPS, are gaining recognition as a key component of modern drug development.

By enabling more predictive and efficient preclinical evaluation, these approaches support earlier and better informed decision making, improve development efficiency, and help reduce long term costs across the drug development process.